Renaissance Technologies
CGEM icon

Renaissance Technologies’s Cullinan Oncology CGEM Stock Holding History

Renaissance Technologies’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Buy
326,811
+2,700
+0.8% +$40.1K 0.01% 1363
2026
Q1 		$4.61M Sell
324,111
-307,595
-49% -$3.95M 0.01% 1423
2025
Q4 		$6.54M Buy
631,706
+102,298
+19% +$923K 0.01% 1153
2025
Q3 		$3.14M Buy
529,408
+194,883
+58% +$1.43M ﹤0.01% 1759
2025
Q2 		$2.52M Sell
334,525
-28,483
-8% -$229K ﹤0.01% 1970
2025
Q1 		$2.75M Buy
363,008
+172,500
+91% +$1.66M ﹤0.01% 1796
2024
Q4 		$2.32M Sell
190,508
-91,292
-32% -$1.31M ﹤0.01% 1962
2024
Q3 		$4.72M Sell
281,800
-139,908
-33% -$2.48M 0.01% 1474
2024
Q2 		$7.35M Buy
421,708
+100,608
+31% +$2.14M 0.01% 1090
2024
Q1 		$5.47M Buy
321,100
+57,012
+22% +$881K 0.01% 1363
2023
Q4 		$2.69M Buy
264,088
+41,388
+19% +$367K ﹤0.01% 1756
2023
Q3 		$2.02M Sell
222,700
-22,900
-9% -$238K ﹤0.01% 1858
2023
Q2 		$2.64M Buy
245,600
+6,400
+3% +$68K ﹤0.01% 1822
2023
Q1 		$2.45M Sell
239,200
-68,500
-22% -$755K ﹤0.01% 1897
2022
Q4 		$3.25M Buy
307,700
+5,505
+2% +$66.9K ﹤0.01% 1763
2022
Q3 		$3.87M Buy
302,195
+8,595
+3% +$116K 0.01% 1596
2022
Q2 		$3.76M Buy
+293,600
New +$3.33M ﹤0.01% 1762
2022
Q1 		– Sell
-26,600
Closed -$410K – 4104
2021
Q4 		$410K Buy
+26,600
New +$531K ﹤0.01% 3174
2021
Q3 		– Sell
-25,982
Closed -$669K – 3512
2021
Q2 		$669K Buy
+25,982
New +$799K ﹤0.01% 2843

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Renaissance Technologies's CGEM Position: Q2 2026 in Review

Renaissance Technologies increased its Cullinan Oncology (CGEM) stake by 0.83% in Q2 2026, buying an estimated $40.1K and bringing the position to 326,811 shares worth $5.95M. The position accounts for 0.01% of the portfolio, ranked #1363.

Renaissance Technologies first reported a position in CGEM in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.35M in Q2 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Renaissance Technologies held 326,811 shares of Cullinan Oncology worth $5.95M as of Q2 2026.
  • Renaissance Technologies bought 2,700 Cullinan Oncology shares in Q2 2026, an estimated $40.1K.
  • Cullinan Oncology made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1363 holding.
  • Renaissance Technologies first reported a position in Cullinan Oncology in Q2 2021 and has held it in 19 quarters since.
  • Renaissance Technologies's Cullinan Oncology position peaked at $7.35M in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.